Research programme: graft-versus-host disease therapeutics - Mallinckrodt/Keio University

Drug Profile

Research programme: graft-versus-host disease therapeutics - Mallinckrodt/Keio University

Alternative Names: GvHD therapeutics - Mallinckrodt/Keio University

Latest Information Update: 21 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator R-Tech Ueno
  • Developer Keio University School of Medicine; Mallinckrodt plc
  • Class
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Dry eyes; Graft-versus-host disease

Most Recent Events

  • 13 Feb 2018 Sucampo Pharmaceuticals has been acquired and merged into Mallinckrodt plc
  • 07 Dec 2015 R-Tech Ueno has been acquired and merged into Sucampo Pharmaceuticals
  • 10 Mar 2014 Early research in Dry eyes in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top